A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast
Florian Dilasser1, Lindsay Rose1, Agnès Quemener2
1Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France.
Abstract:
The dysregulation of RAC1 activity is associated with neoplastic transformation, metastasis, and poor prognosis in several cancers. Here, we discover in silico a series of RAC1 inhibitors. The most potent of them, A41, specifically inhibits RAC1 with an original mechanism of action. We characterize A41 as a reversible inhibitor that competes with guanine nucleotide binding specifically on RAC proteins. A41 efficiently blocks RAC1 activity and RAC1-dependent cell functions including cell adhesion and migration. Chronic administration of A41 exhibits anti-metastatic effects in mouse models of triple-negative breast cancer, leading to an increase in the survival rate. Our findings suggest that this molecule, A41, could be a promising and powerful therapeutic agent for limiting invasive cancers in patients.
Insights
Researchers identified A41, a novel RAC1 inhibitor, that blocks cancer cell migration and metastasis. This molecule shows promise as a therapeutic agent for invasive cancers, improving survival rates in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Dysregulated RAC1 activity is linked to cancer development, metastasis, and poor patient prognosis.
- Targeting RAC1 offers a potential strategy for cancer therapy.
Purpose of the Study:
- To discover and characterize novel inhibitors of RAC1.
- To evaluate the therapeutic potential of the identified RAC1 inhibitor, A41, in preclinical cancer models.
Main Methods:
- In silico screening to identify RAC1 inhibitors.
- Biochemical assays to characterize inhibitor mechanism of action.
- In vitro assessment of RAC1-dependent cell functions (adhesion, migration).
- In vivo studies in mouse models of triple-negative breast cancer.
Main Results:
- A novel RAC1 inhibitor, A41, was identified with a unique mechanism of action.
- A41 acts as a reversible inhibitor, competing with guanine nucleotide binding on RAC proteins.
- A41 effectively inhibits RAC1 activity, cell adhesion, and migration.
- Chronic A41 administration demonstrated anti-metastatic effects and improved survival in preclinical models.
Conclusions:
- A41 is a potent and specific RAC1 inhibitor with anti-metastatic properties.
- A41 represents a promising therapeutic candidate for invasive cancers.
- Targeting RAC1 with A41 could offer a new strategy for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity